Clinical Trials

Dual Inhibition of MYCN and MDM2: A New Hope for Cancer Therapy
Research & Development Dual Inhibition of MYCN and MDM2: A New Hope for Cancer Therapy

In the relentless pursuit of enhanced cancer treatments, recent research has shed light on the dual inhibition of MYCN and MDM2 as a promising strategy. Both MYCN and MDM2 are vital oncogenes implicated in various tumorigenic processes. Their simultaneous targeting might revolutionize the

Can New Drug Regimens Really Eliminate Drug-Resistant TB?
Research & Development Can New Drug Regimens Really Eliminate Drug-Resistant TB?

Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide, with drug-resistant strains posing a significant challenge to global health. Recent advancements in TB treatment, particularly for drug-resistant forms, offer new hope. This article explores the potential of new drug

Position-Specific Hallmarks: Revealing Tumor Spatial Organization for Treatment
Research & Development Position-Specific Hallmarks: Revealing Tumor Spatial Organization for Treatment

New research shines light on position-specific hallmarks of cancer, diving deeply into the contemporary understanding of cancer and focusing on the specific expression patterns of cancer hallmarks within tumors. The fundamental question it addresses is, "What is a tumor?"—a crucial query when

Breakthrough in Transthyretin Structure Could Revolutionize ATTR Treatment
Research & Development Breakthrough in Transthyretin Structure Could Revolutionize ATTR Treatment

Recent research led by scientists at Scripps Research has unveiled groundbreaking insights into the structure and behavior of the protein transthyretin, which could have significant implications for the treatment of transthyretin amyloidosis (ATTR). This disease, marked by the misfolding of

AI-Driven Evaluations Pave the Way for Enhanced Aging Interventions
Tech & Innovation AI-Driven Evaluations Pave the Way for Enhanced Aging Interventions

The recent study conducted by researchers at the Yong Loo Lin School of Medicine, National University of Singapore, and the Institute for Biostatistics and Informatics in Medicine and Aging Research, Rostock University Medical Center, delved into the promising potential of advanced AI tools,

Can Efruxifermin Offer New Hope for MASH-Induced Liver Cirrhosis?
Research & Development Can Efruxifermin Offer New Hope for MASH-Induced Liver Cirrhosis?

The potential breakthrough in treating liver cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH) has come from a recent study by Akero Therapeutics. Efruxifermin, an experimental drug, has shown significant promise in reversing liver damage in patients suffering from this

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later